Search

Displaying results 1841 - 1850 of 8468 in total
  1. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    This drug contains sulfhydryl groups which are released after erdosteine undergoes hepatic first pass metabolism. … Erdosteine has been shown to be safe and well tolerated in clinical trials.

  2. Drug

    Quaternium-15

    go.drugbank.com/drugs/DB14198
    Approved

    Quaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics. … In 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].

  3. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    [A32825] Pyrithione derivatives, such as [DB06815] and sodium pyrithione, are widely used as cosmetic preservatives and as anti-dandruff agents in shampoos. … Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available.

  4. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  5. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].

  6. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.

  7. Drug

    Light green SF yellowish

    go.drugbank.com/drugs/DB11183
    Approved

    Although it has been used as a food colorant, it was discontinued from the market due to low popularity which are possibly due to low durability of the dye and increased tendency of the dye to fade. … Light green SF yellowish is also available as sterile strips used as a diagnostic agent when superficial corneal or conjunctival tissue change is suspected.

  8. Drug

    Cefoperazone

    go.drugbank.com/drugs/DB01329
    ApprovedInvestigationalWithdrawn

    While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.

  9. Drug

    Sulfamerazine

    go.drugbank.com/drugs/DB01581
    ApprovedVet approvedWithdrawn

    A sulfanilamide that is used as an antibacterial agent.

  10. Drug

    Ferric cation

    go.drugbank.com/drugs/DB13949
    ApprovedWithdrawn

    Iron deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality